Thus GS-1101 displays a dual mechanism of action against CLL, directly decreasing BCR-induced CLL cell survival (see above) and inhibiting chemokine-dependent interactions that retain CLL cells in survival-promoting tissue microenvironments. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.